New CEO at Polyplus-transfection
This article was originally published in Scrip
Executive Summary
Polyplus-transfection (France), a privately held company developing solutions for molecular and cellular biology, today has appointed Mark Bloomfield CEO. He succeeds Frédéric Perraud, who continues as chief operating officer and deputy CEO. Mr Bloomfield has more than 15 years' senior sales, commercial leadership and business management experience with companies working in biotechnology tools and analytical instruments.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.